Mylan Laboratories Ltd
Mylan Laboratories Limited,incorporated in India, listed on the Bombay Stock Exchange Limited, the company is engaged in the manufacture and trading of Pharmaceuticals
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE 13.4 %
- ROE 20.1 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 87.8% CAGR over last 5 years
Cons
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.1,358 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| 1,159 | 1,652 | 1,735 | 2,279 | 2,778 | 3,244 | 4,120 | 5,617 | 6,985 | |
| 1,109 | 1,471 | 2,032 | 1,988 | 2,739 | 2,543 | 3,289 | 4,589 | 6,370 | |
| Operating Profit | 50 | 181 | -297 | 291 | 40 | 701 | 830 | 1,028 | 615 |
| OPM % | 4% | 11% | -17% | 13% | 1% | 22% | 20% | 18% | 9% |
| 250 | 50 | 49 | 58 | 841 | 75 | 19 | -10 | 1,358 | |
| Interest | 29 | 75 | 99 | 156 | 126 | 52 | 75 | 77 | 255 |
| Depreciation | 34 | 54 | 61 | 70 | 82 | 104 | 108 | 128 | 367 |
| Profit before tax | 237 | 102 | -408 | 122 | 673 | 620 | 666 | 813 | 1,352 |
| Tax % | 16% | 26% | 13% | 72% | 20% | 28% | 31% | 42% | 20% |
| 200 | 76 | -461 | 34 | 538 | 447 | 457 | 473 | 1,076 | |
| EPS in Rs | 4.95 | -29.56 | 1.94 | 32.16 | 27.25 | 28.61 | 30.04 | 69.15 | |
| Dividend Payout % | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | 29% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 88% |
| 3 Years: | 19% |
| TTM: | 15% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 24% |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 37 |
| Reserves | 936 | 1,019 | 584 | 622 | 1,184 | 1,617 | 1,830 | 2,410 | 4,310 |
| 1,234 | 1,667 | 1,698 | 2,025 | 927 | 1,075 | 1,463 | 2,062 | 6,629 | |
| 872 | 730 | 682 | 907 | 829 | 1,300 | 1,691 | 1,925 | 3,637 | |
| Total Liabilities | 3,073 | 3,446 | 2,995 | 3,585 | 2,972 | 4,023 | 5,016 | 6,429 | 14,614 |
| 1,672 | 2,005 | 1,658 | 1,886 | 1,251 | 1,544 | 1,767 | 1,979 | 6,322 | |
| CWIP | 124 | 36 | 122 | 180 | 134 | 87 | 116 | 135 | 1,021 |
| Investments | 45 | 29 | 30 | 42 | 17 | 17 | 0 | 0 | 154 |
| 1,232 | 1,376 | 1,185 | 1,476 | 1,570 | 2,374 | 3,133 | 4,314 | 7,116 | |
| Total Assets | 3,073 | 3,446 | 2,995 | 3,585 | 2,972 | 4,023 | 5,016 | 6,429 | 14,614 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| 288 | 8 | 66 | 126 | 336 | 231 | 130 | 358 | 359 | |
| -1,271 | -136 | -196 | -285 | -129 | -344 | -355 | -831 | -5,796 | |
| 884 | 325 | -166 | 162 | -254 | 112 | 232 | 501 | 5,465 | |
| Net Cash Flow | -98 | 197 | -296 | 2 | -46 | -1 | 8 | 28 | 29 |
| Free Cash Flow | 57 | -168 | -133 | -154 | 7 | 231 | -232 | 368 | 376 |
| CFO/OP | 655% | 3% | -34% | 57% | 1,179% | 57% | 35% | 66% | 107% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 125 | 74 | 84 | 105 | 74 | 73 | 98 | 87 | 119 |
| Inventory Days | 234 | 193 | 230 | 194 | 219 | 262 | 253 | 232 | 256 |
| Days Payable | 265 | 163 | 148 | 137 | 126 | 126 | 140 | 133 | 148 |
| Cash Conversion Cycle | 93 | 104 | 165 | 161 | 168 | 209 | 211 | 186 | 226 |
| Working Capital Days | 91 | 79 | 109 | 99 | 128 | 144 | 148 | 155 | 177 |
| ROCE % | 7% | -12% | 11% | 16% | 25% | 24% | 27% | 13% |
Insights
In beta| Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global HIV Patients Treated (Total) Million Persons |
|
|||||||||||
| Gross Current Asset (GCA) Days Days ・Standalone data |
||||||||||||
| Developing World HIV Market Share % |
||||||||||||
| Global ARV Market Share (Treatment Capacity) % |
||||||||||||
| Number of Manufacturing Facilities (India) Units ・Standalone data |
||||||||||||
| R&D Expense as % of Sales % ・Standalone data |
||||||||||||
Documents
Announcements
No data available.
Annual reports
No data available.